Psilocybin-Assisted Psychotherapy: Current Research and Clinical Guidelines for Anxiety, Depression, and PTSD

This episode delves into the burgeoning field of psychedelics, specifically psilocybin, as a treatment for anxiety, depression, and PTSD, particularly for the over 50% of patients who do not respond to conventional treatments like SSRIs and atypical antipsychotics. Dr. Snipes explains the neurobiological mechanisms, highlighting that while SSRIs are 5-HT2A receptor antagonists, psychedelics like psilocybin are agonists, both of which can impact depression symptoms. Psychedelics initiate a cascade of neurobiological changes, including the attenuation of the default mode network (DMN) and increased activity in the executive control network (ECN), which ultimately facilitates the relaxation of deeply held, pathological beliefs.\n\nA key distinction is made between the mechanisms of action of traditional antidepressants and psychedelics, noting that the 5-HT2A receptor plays a crucial role, with both agonists and antagonists potentially offering relief depending on individual neurochemistry. The podcast emphasizes that psychedelics are not a universal cure and can exacerbate conditions like anxiety or schizophrenia, underscoring the necessity of careful patient screening and medical supervision. A critical aspect of psilocybin-assisted therapy is the "set and setting," where the patient's mindset and the therapeutic environment profoundly influence the experience and outcomes, differentiating it sharply from recreational use.\n\nThe therapeutic protocol for psilocybin-assisted therapy is detailed in three phases: preparation, acute psychedelic experience, and integration. The preparation phase involves multiple sessions with two clinicians to build rapport, establish safety, identify core beliefs, and manage expectations. During the 6-8 hour acute experience, psilocybin is administered to help patients process beliefs by calming the amygdala and DMN, allowing access to traumatic memories without being overwhelmed. The integration phase, occurring during and after the acute experience, involves processing insights with therapists, which is deemed essential for both effectiveness and safety, promoting neuroplasticity, neurogenesis, and fear extinction.\n\nThe renewed interest in psychedelics is driven by the high rates of treatment-resistant depression and the FDA's granting of breakthrough therapy status to psilocybin in 2019. While many studies are open-label and small-scale, they demonstrate rapid, significant, and sustained improvements for up to six months post-treatment. The episode also touches on the historical use of psilocybin for "concentration camp syndrome" (now PTSD) in the Netherlands before 1980. Potential negative effects such as panic attacks, paranoia, and the rare but serious hallucinogenic persistent perceptive disorder (HPPD) are acknowledged, reinforcing the need for controlled, supervised administration within a comprehensive therapeutic framework.

"SSRIS and atypical antipsychotics actually blunt the action of the 5 h2a postsynaptic receptors they work against them so they antagonize them."

"For more than 50 percent of the clinical population ssris and atypical antipsychotics do not work underscoring the multiplicity of causes of depression."

"Psychedelics like lsd mescaline and psilocybin are 5 h2a and to a lesser extent 5 h2c receptor agonists which may result in antidepressant activity."

"Psychedelics initiate a cascade of neurobiological changes that manifest in multiple ways and ultimately culminate in the relaxation of high-level beliefs."

"The purpose of psychedelic therapy is to harness the opportunity afforded by this belief relaxation to achieve a healthy revision of pathological beliefs."

"The experience somebody has when they're under the influence of psychedelics is greatly influenced by people's expectations by their beliefs by their feeling of safety in the environment in which they are located when they ingest the substance."

"The psychotherapeutic elements of this approach are essential for both effectiveness and safety."

"Reduced amygdala reactivity during emotional processing... can be a gateway for people to actually access memories and thoughts and feelings about an event without feeling completely consumed by them."